Clinical Trials Browser

Interventional × Dasatinib × Head & Neck × Clear all

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT05724329 2024-09-19

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT00882583 2019-01-09

Dasatinib

Phase 1 Terminated

22 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00859937 2018-04-20

Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

Phase 2 Completed

55 enrolled 8 charts

Salivary Gland Neoplasms

NCT01488318 2018-01-05

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Phase 2 Terminated

21 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT00779389 2016-01-13

Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

Phase 1 Completed

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT00507767 2014-10-01

Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2 Completed

15 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms